Abstract: The present invention relates to an MRS 1D or 2D method and system for obtaining spectral data of the brain of a subject and using neurochemical markers to enable whether a subject is experiencing acute pain, and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of Fuc II, III, IV, VII and lactate.

Abstract: A method and system enabling a determination of the risk of developing breast cancer of a subject, comprises using a magnetic resonance spectroscopy device to obtain the level of the spectral signal at 3.15 and 3.19 ppm, within the breast tissue of the subject, and comparing the level of the spectral signal obtained in the first step with a reference level of a spectral signal at 3.15 and 3.19 ppm of the breast of a healthy subject, to determine whether the level of the signal obtained in the first step exceeds the reference level of a healthy subject is comparable to that of a subject known to be at elevated risk; or is elevated to the level of persons known to be carrying a gene mutation.

Abstract: An integrated MRI and MRS system includes a plurality of different classifiers for detecting the likelihood of the new data to be one of the different diseases/conditions in different body organs, and even the progression of the disease, disease state and condition within that organ. An interface module receives information on the individual including region of the body and potential disease/condition; and provides this information to a data analysis unit which automatically dictates which coil, the scanning protocol and classifier.

Abstract: A method and system provides the ability to detect density of a women's breast by obtaining the concentration of at least one selected biochemical in the breast using a spectrometer, and comparing the concentration obtained with reference measurements which correlate breast density with concentration of the at least one selected biochemical.

Abstract: A method and system for detecting the presence of BRCS carriers in breast tissue, comprises obtaining spectral data from breast tissue using a magnetic resonance spectroscopy device and producing spectral data by said device which provides chemical markers to enable detection of whether the breast tissue contains BRCA carriers.

Abstract: A method and system for monitoring therapeutic interventions for treating a patient with PTSD comprises using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in the brain of the patient before treatment, treating the patient with at least one treatment protocol, after treatment, obtaining post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and comparing the results of the pre-treatment and post-treatment data to enable a determination of the effectiveness of the treatment.

Abstract: A method and system obtains spectral data from the brain of a person undergoing treatment for pain to determine whether the concentration of new chemicals including fucosylated glycans indicates fucosylated glycan concentration levels of a person experiencing pain or returning to normal levels of a healthy person who is not experiencing pain, to assess the person's response to treatment and progress.

Abstract: An integrated MRI and MRS system includes a plurality of different classifiers for detecting the likelihood of the new data to be one of the different diseases/conditions in different body organs, and even the progression of the disease, disease state and condition within that organ.

Abstract: One dimensional (1D) and two dimensional (2D) MR spectroscopy of the brain provides an objective test for pain and level of pain. There are two ways of evaluating the data. The first is conventional analysis of the 2D MRS. The second us the use of data mining methods such as testing for correlation between wavelet-based features and self-reported pain intensity, the MBDA method. Both found multiple spectral regions that were highly correlated with self-reported pain. Two of these spectral regions are consistent with changes to the recently assigned substrate ?-L Fucose and the Fuc-?(1-2) glycans in the human brain. There are common features recorded compared with prior reports using the MBDA method to evaluate pain associated with spinal cord injury and low back pain.

Abstract: A method and system for enabling a practitioner to detect acute stress disorder and PTSD using fMRI comprises looking at functional connectivity dynamics within the visual pathways, limbic, thalamic, paralimbic and prefrontal brain networks observed when individuals are viewing visual images of different facial expressions.

Abstract: The present invention relates to a method and system for using neurochemical markers to enable whether a subject is experiencing acute stress, trauma, or PTSD and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of NAA, glutamine or Fuc IV and lactate and a decrease of Fuc IV during the transition from acute stress to PTSD.

Abstract: The present invention relates to an MRS 1D or 2D method and system for obtaining spectral data of the brain of a subject and using neurochemical markers to enable whether a subject is experiencing acute pain, and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of Fuc II, III, IV, VII and lactate.

Abstract: The present invention relates to a method and system for using neurochemical markers to identify different types of pain, including chronic and acute, and providing the capacity to monitor response to therapy on an individual basis. The present invention relates to a method and system for using neuro biomarkers to identify pain of different types and origins, and the capacity to monitor response to therapy on a personalized basis.

Abstract: A method for producing a biomarker indicative of a repetitive head injury in a subject using a magnetic resonance imaging (MRI) system is provided. Two-dimensional spectroscopic data is acquired from a subject using an MRI system. From the two-dimensional spectroscopic data, a two-dimensional spectrum is produced. The two-dimensional spectrum contains spectral information indicated by a first spectral dimension and a second spectral dimension. Such a two-dimensional spectrum may include diagonal peaks and off-diagonal, or cross-peaks. In such an instance, each cross peak may indicate, for example, scalar coupling between the two protons it connects on the diagonal. However, depending on the type of method used, different types of coupling may also be present. Using the two-dimensional spectrum, a biomarker indicative of repetitive head injury in the subject is identified, and may be used to produce a report indicating a status or regression of a neurological dysfunction.

Abstract: A method and system for detecting the presence of BRCS carriers in breast tissue, comprises obtaining spectral data from breast tissue using a magnetic resonance spectroscopy device and producing spectral data by said device which provides chemical markers to enable detection of whether the breast tissue contains BRCA carriers.

Abstract: A system and method identifies different components of the pain experience (nociceptive (tissue damage), neuropathic (nerve damage) and psychological) and their relative contributions by the use of magnetic resonance spectroscopy (MRS) to measure absolute and relative concentrations of metabolites in specific brain regions in the central nervous system or brain. The system and method can be used as a diagnostic tool for the assessment of the relative contribution of different aspects of the pain experience as well as monitoring of response to interventions directed at modifying these components.

Abstract: Methods for low-power in vivo localized multi-dimensional correlated magnetic resonance spectroscopy (“MRS”) are provided. Low-power adiabaticity is achieved, generally, using gradient-modulated radio frequency pulses for localization and mixing. The provided pulse sequences also provide a mechanism for longitudinal mixing, which significantly increases the efficiency of magnetization transfer and thereby increases signal-to-noise ratio.

Abstract: A method for producing a biomarker indicative of a repetitive head injury in a subject using a magnetic resonance imaging (MRI) system is provided. Two-dimensional spectroscopic data is acquired from a subject using an MRI system. From the two-dimensional spectroscopic data, a two-dimensional spectrum is produced. The two-dimensional spectrum contains spectral information indicated by a first spectral dimension and a second spectral dimension. Such a two-dimensional spectrum may include diagonal peaks and off-diagonal, or cross-peaks. In such an instance, each cross peak may indicate, for example, scalar coupling between the two protons it connects on the diagonal. However, depending on the type of method used, different types of coupling may also be present. Using the two-dimensional spectrum, a biomarker indicative of repetitive head injury in the subject is identified, and may be used to produce a report indicating a status or regression of a neurological dysfunction.

Abstract: Methods for low-power in vivo localized multi-dimensional correlated magnetic resonance spectroscopy (“MRS”) are provided. Low-power adiabaticity is achieved, generally, using gradient-modulated radio frequency pulses for localization and mixing. The provided pulse sequences also provide a mechanism for longitudinal mixing, which significantly increases the efficiency of magnetization transfer and thereby increases signal-to-noise ratio.

Abstract: A system and method identifies different components of the pain experience (nociceptive (tissue damage), neuropathic (nerve damage) and psychological) and their relative contributions by the use of magnetic resonance spectroscopy (MRS) to measure absolute and relative concentrations of metabolites in specific brain regions in the central nervous system or brain. The system and method can be used as a diagnostic tool for the assessment of the relative contribution of different aspects of the pain experience as well as monitoring of response to interventions directed at modifying these components.